Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 29.55% is 100% above its 5-year average of -12475.37%, near the high end of its 5-year range (-534112.50%–72.14%).
101.01% above its 12-month average of -2937.99%.
Reported quarterly EBITDA margin; no daily interpolation. Q1 FY2026 (2026-03-31): -6941.14%.
EBITDA MARGIN
29.55%
EBITDA MARGIN AVG TTM
-2937.99%
EBITDA MARGIN AVG 3Y
-71951.49%
EBITDA MARGIN AVG 5Y
-12475.37%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+101.01%
CURRENT VS 3Y AVG
+100.04%
CURRENT VS 5Y AVG
+100.24%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Keros Therapeutics, Inc.
Market Cap
$218.04M
EBITDA Margin
29.55%
TTM Avg
-2937.99%
3Y Avg
-71951.49%
5Y Avg
-12475.37%
Market Cap
$219.48M
EBITDA Margin
-252.79%
TTM Avg
-276.80%
3Y Avg
-348.01%
5Y Avg
-340.44%
Market Cap
$213.78M
EBITDA Margin
-847.24%
TTM Avg
-1408.92%
3Y Avg
-1408.92%
5Y Avg
-1408.92%
Market Cap
$212.75M
EBITDA Margin
-533986.11%
TTM Avg
-544963.54%
3Y Avg
-316138.98%
5Y Avg
-211520.31%
Market Cap
$212.25M
EBITDA Margin
12.17%
TTM Avg
10.71%
3Y Avg
-1.62%
5Y Avg
-12.53%
Market Cap
$210.38M
EBITDA Margin
43.70%
TTM Avg
-4.00%
3Y Avg
-127.66%
5Y Avg
-437.76%
Market Cap
$210.02M
EBITDA Margin
-611.99%
TTM Avg
-293.95%
3Y Avg
-196.05%
5Y Avg
-196.05%
Market Cap
$210.24M
EBITDA Margin
66.70%
TTM Avg
45.54%
3Y Avg
40.95%
5Y Avg
43.86%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | $218.04M | 29.55% | -2937.99% | -71951.49% | -12475.37% |
| Profound Medical Corp. (PROF)vs › | $219.48M | -252.79% | -276.80% | -348.01% | -340.44% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $213.78M | -847.24% | -1408.92% | -1408.92% | -1408.92% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $212.75M | -533986.11% | -544963.54% | -316138.98% | -211520.31% |
| Niagen Bioscience Inc (NAGE)vs › | $212.25M | 12.17% | 10.71% | -1.62% | -12.53% |
| Vogenx Inc. (VOGX)vs › | $224.23M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $210.38M | 43.70% | -4.00% | -127.66% | -437.76% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.02M | -611.99% | -293.95% | -196.05% | -196.05% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $210.24M | 66.70% | 45.54% | 40.95% | 43.86% |
| Biodesix, Inc. (BDSX)vs › | $227.60M | -25.05% | -32.88% | -63.97% | -61.52% |
Gross Margin
94.7%
EBITDA Margin
29.6%
Operating Margin
28.9%
Net Margin
-553.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-03-31 | -6941.14% |
| 2025-12-31 | -7498.70% |
| 2025-09-30 | -105.10% |
| 2025-06-30 | -217.12% |
| 2025-03-31 | 72.14% |
| 2024-12-31 | -1739.71% |
| 2024-09-30 | -15036.86% |
| 2024-06-30 | -135494.59% |
| 2024-03-31 | -58079.52% |
| 2023-12-31 | -32313.29% |
| 2023-09-30 | -534112.50% |
| 2021-12-31 | -22.82% |
| 2021-06-30 | -15347.00% |
| 2019-12-31 | -106.76% |
| 2019-09-30 | -90.84% |
| 2019-06-30 | -104.08% |
| 2019-03-31 | -112.52% |
